



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No. 40399/216/NIHD

In re patent application of

Mary STRACKE et al.

Group Art Unit: 1806

Serial No. 07/822,043

Examiner: B. Celsa

Filed: January 17, 1992

For: AUTOTAXIN: MOTILITY STIMULATING PROTEIN USEFUL IN
CANCER DIAGNOSIS AND THERAPY

181a
Sml
9/28/93

AMENDMENT AND REQUEST FOR RECONSIDERATION
UNDER 37 CFR §1.111

RECEIVED

SEP 24 1993

Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

In response to the Office Action mailed March 4, 1993, the period of response to which has been extended to September 7, 1993, via the accompanying petition and payment of the required fee (September 4, 1993, falling on a weekend), applicants request that the PTO amend the above-identified application as detailed below.

IN THE SPECIFICATION

Page 35, line 14, delete "ATX-101" and insert --ATX-102--;
line 20, delete "ATX-101" and insert --ATX-102--.

IN THE CLAIMS

Please cancel claims 3-6 and 16-17, and add the following claims:

18. A polypeptide selected from human autotaxin protein in homogeneous form or a fragment of said protein, wherein
- (A) said protein has an isoelectric point of about 7.7, a molecular weight of about 125 kDa, as determined SDS-polyacrylamide gel electrophoresis under reducing conditions, and induces a motility in human A2508 melanoma cells which is inhibited by pertussis toxin;

Sub. B1
Q1

a